摘要
总结8例多发性硬化使用β-干扰素治疗的护理,认为在护理中应做到:密切观察病情变化,做好心理支持,加强基础护理,正确功能锻炼,注意用药作用和副作用的观察,同时做好出院指导。
出处
《杭州师范学院学报（医学版）》
2007年第2期117-118,共2页
Journal of Hangzhou Teachers College :Medical Edition
参考文献5
-
1黄友歧 周孝达 等.神经病学[M].北京:人民卫生出版社,1992,2.190.
-
2匡玉吉,焦淑成,李炜.β-干扰素与多发性硬化症的治疗[J].生物技术通讯,2006,17(3):457-459. 被引量：3
-
3谢琰臣,张华,许贤豪.干扰素-β治疗多发性硬化[J].中国神经免疫学和神经病学杂志,2006,13(2):124-127. 被引量：10
-
4陈胜云.干扰素在多发性硬化治疗中的应用[J].中国全科医学,2004,7(6):403-403. 被引量：2
-
5边吉,周慧芳.β干扰素致肝损害[J].药物不良反应杂志,2004,6(3):204-204. 被引量：1
二级参考文献38
-
1Goodin DS, Frohman EM, Garmany GP Jr, et al.Disease modifying therapies in multiple selerosis:report of the Therapeutics and technology assessment subcommittee of the american academy of neurology and the MS council for clinical practice guidelines[J].Neurology, 2002,58 (2) : 169-178.
-
2Rudiek RA, Lee JC, Simon J, et al. Defining inter feron beta response status in multiple sclerosis patients[J]. Lancet,2004,364(9444) : 1489-1496.
-
3Gilli F, Marnetto F, Caldano M, et al. Biological responsivenes to first injections of interferon-beta in patients with multiple selerosis[J]. J Neuroimmunol,2005,158 (1-2) : 195-203.
-
4Billiau A, Kieseier BC, Hartung HP. Biologie role of interferon beta in multiple selerosis[J]. J Neurol,2004(suppl2) ,251: Ⅱ 10-14.
-
5IFN-β Multiple Sclerosis Study Group, University of British Columbia MS/MR1 Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial[J]. Neurology, 1995,45 (7) : 1277-1285.
-
6Jocobs LD, Cookfair DL, Rudiek RA, et al. Intra-muscular interferon beta-1a for disease progression in relapsing multiple selerosis[J]. Ann Neurol, 1996, 89(3) :285-294.
-
7PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis [J]. Lancet, 1998, 352(9139) : 1498-1504.
-
8European Study Group on interferon beta-lb in secondary progressive MS. Placebo- controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis [J]. Lancet,1998,352(9139): 1491-1497,
-
9Barkhof F, van Waesberghe JH, Filippi M, et al. T1 hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment[J].Brain, 2001,124(7) : 1396-1402.
-
10IFN-β1b SPM Study Group(McFarland HF, et al).Subcutaneous IFN beta-1b in secondary progressive multiple sclerosis [ M]. San Diego: 52nd Annual Meeting American Academy of Neurology, 2000.1-25.
共引文献13
-
1徐桂红,巩杰,陈念嫦.干扰素β-1α治疗多发性硬化副作用的护理[J].海南医学,2008,19(S1):92-93.
-
2朱静吟,褚仁远,瞿小妹.渐变多焦镜与非渐变镜配戴者阅读前后脑血流速度的比较[J].老年医学与保健,2006,12(2):110-113.
-
3徐桂红,黄美莲,陈敏.18例视神经脊髓炎的临床护理[J].现代护理,2007,13(09Z):2538-2539.
-
4王冰雁.多发性硬化的治疗进展[J].临床荟萃,2007,22(22):1669-1671.
-
5徐桂红,丘伟,沈利平.干扰素β-1α治疗多发性硬化临床观察与护理[J].齐齐哈尔医学院学报,2007,28(21):2652-2653. 被引量：1
-
6徐桂红,钟月桂,陆正齐.多发性硬化患者的护理[J].护士进修杂志,2008,23(21):1961-1963. 被引量：4
-
7徐蕙,刘德辉,郭霄峰.猪β-干扰素的研究进展[J].中国畜牧兽医,2009,36(12):120-122. 被引量：1
-
8关东升,高颖,娄丽霞,朱陵群.益肾达络饮对实验性自身免疫性脑脊髓炎NF-κB信号传导通路的影响[J].中国中医基础医学杂志,2012,18(7):732-735. 被引量：8
-
9李柳萍,杨胥微,黄志斌,喇文军,王妍.重组人干扰素β1a的纯化及其理化性质[J].中国生物制品学杂志,2013,26(6):834-839. 被引量：1
-
10王妍,张丽君,黄志斌,张英,梁雯荻.生物反应器培养分泌重组人干扰素β1a的CHO细胞工艺的建立[J].中国生物制品学杂志,2013,26(10):1493-1497. 被引量：2
同被引文献20
-
1杨云凯,张振龙,刘建源,邓宛明,崔春青.重组人干扰素βSer^(17)的结构及活性分析[J].中国生物制品学杂志,2005,18(4):297-299. 被引量：1
-
2史艳秋,陈畅,顾黎,邹思湘,宋静,王鹏.重组人β干扰素在DHFR^--CHO细胞中的高效表达[J].中国生化药物杂志,2006,27(3):129-133. 被引量：7
-
3雷楗勇,张莲芬,杨健良,金坚.人β干扰素-血清白蛋白融合蛋白在毕赤酵母中的分泌表达[J].中国生物工程杂志,2006,26(7):13-18. 被引量：20
-
4Filippini G, Munari L,Incorvaia B, et al. Interferons in relapsing remitting multiple sclerosis:a systematic review [J]. Lancet, 2003, 361 (9357) :545-552.
-
5Durelli L, Barfbero P, Verdun E, et al. Reducing interferon beta dose in chronically-treated MS patients may have long-term deleterious effects on disease activity [J]. Neurology, 2003, 60 (5Suppl 1): A167-A168.
-
6Kagawa T, Morizane T, Saito H, etal. A pilot study of long-term weekly interferon-beta administration for chronic hepatitis B [J]. Am J Gastroenterol, 1993, 88 (2): 212-216.
-
7Suzuki H, Nichigaki K, Gunji A. Toray IFN Research Group: Treatment of chronic non-A, non-B hepatitis with human interferon-β. a randomized controlled trial with different durations [ in Japanese] [J]. Kan Tan Sui, 1994, 23: 1065-1079.
-
8Takano S, Satomura Y, Omata M. Effects of interferon beta on non-A, non-B acute hepatitis: a prospective, randomized, controlleddose study. Japan Acute Hepatitis Cooperative Study Group[J]. Gastroemenrology, 1994, 107 (3) : 805-811.
-
9Schonfeld A, Nitke S, Schattner A, et al. Intramuscular human interferon-beta injections in treatment of condylomata [J ]. Lancet, 1984, 1 (8385): 1038-1042.
-
10徐桂红,丘伟,沈利平.干扰素β-1α治疗多发性硬化临床观察与护理[J].齐齐哈尔医学院学报,2007,28(21):2652-2653. 被引量：1
二级引证文献4
-
1赵东丽,吴敏红,施丽华.利比致过敏反应1例[J].海峡药学,2011,23(12):257-258.
-
2徐雷,冯若飞,李向茸,张海霞,谢晶莹,包晓婧,马玉梅,马忠仁.猪β干扰素真核表达载体pEGFP-C1-IFN-β的构建及在CHO细胞中的表达[J].中国兽医科学,2015,45(7):751-757. 被引量：4
-
3唐丽媛,李楠,缪希松,王元,芮丹云,童毅,王波,李臣,句红萍,谢力.重组Ser^(17)突变型hIFN-β腺病毒的构建及其对结肠癌细胞的增殖抑制作用[J].中国免疫学杂志,2017,33(2):196-200.
-
4徐德璐,胡雷,兰天龙,钟飞,刘艳菊,周博宇.食蟹猴sc重组人干扰素β-1a注射液30d安全性评价[J].药物评价研究,2019,42(8):1537-1543.
